[Anticytokine therapy in the treatment of patients with chronic heart failure].
Sychev
A V
AV
Mareev
V Iu
VIu
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000037:antagonists & inhibitors*; D004195:Disease Models, Animal; D000068800:Etanercept; D006333:Heart Failure / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000627:therapeutic use; D007136:Immunoglobulins / Q000627:therapeutic use; D000069285:Infliximab; D051379:Mice; D010919:Placebos; D011379:Prognosis; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D016207:Cytokines; D007074:Immunoglobulin G; D007136:Immunoglobulins; D010919:Placebos; D018124:Receptors, Tumor Necrosis Factor; D011993:Recombinant Fusion Proteins; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept